Molecular sampling of prostate cancer: a dilemma for predicting disease progression

Molecular sampling of prostate cancer: a dilemma for predicting disease progression

Show other versions (1)

Background: Current prostate cancer prognostic models are based on pre-treatment prostate specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are inadequate to accurately predict disease progression. Hence, we sought to develop a molecular panel for prostate can...

Full description

Bibliographic Details
Main Authors: Sboner, Andrea, Demichelis, Francesca, Calza, Stefano, Pawitan, Yudi, Setlur, Sunita R., Hoshida, Yujin, Perner, Sven, Adami, Hans-Olov, Fall, Katja, Mucci, Lorelei A., Kantoff, Philip W., Stampfer, Meir, Andersson, Swen-Olof, Varenhorst, Eberhard, Johansson, Jan-Erik, Gerbstein, Mark B., Golub, Todd R., Rubin, Mark A., Andren, Ove
Other Authors: Harvard University--MIT Division of Health Sciences and Technology
Format: Article
Language:en_US
Published: BioMed Central Ltd. 2012
Online Access:http://hdl.handle.net/1721.1/69537

Similar Items

Similar Items